Immunotherapy-Radiation combo shows promise in tough lung cancer
NCT ID NCT02402920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety and best dose of the immunotherapy drug pembrolizumab when combined with chemotherapy and radiation for people with small cell lung cancer. The goal was to see if adding pembrolizumab helps the immune system fight the cancer more effectively. The study included 83 participants with either limited or extensive stage disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New PET tracer could spot cancers that standard scans overlook
- Lung cancer trial tests two new combo therapies against tough disease
- Could a PARP inhibitor boost chemo for tough lung cancer?
- Cancer combo trial pulled before starting